par Neuzillet, Y;Guy, L;Long, J-A;Zini, L;Chevreau, Christine;Duclos, Brigitte;Escudier, Bernard;Gimel, P;Joly, Francisca;Lang, Hervé;Mejean, A;Oudard, S;Roumeguere, Thierry
Référence Progrès en urologie, 21 Suppl 2, page (S27-S33)
Publication Publié, 2011-03
Référence Progrès en urologie, 21 Suppl 2, page (S27-S33)
Publication Publié, 2011-03
Article révisé par les pairs
Résumé : | Three clinical cases have shown the superiority of sunitinib in first line therapy intermediate risk metastatic clear cell renal carcinoma and a best safety of bevacizumab plus interferon, the current lack of high level of evidence arguments for the neo-adjuvant treatment of kidney cancer, the importance to prevent mucositis during a mTOR inhibitors treatment and the diagnostic pitfalls of its pulmonary complications. |